Marksans Pharma Ltd.

Marksans Pharma receives USFDA approval for generic Benzonatate capsules (100mg & 200mg) to treat persistent cough and lung infections.

Unifi Capital sold a 1.6% stake in Marksans Pharma for nearly Rs 168 crore through an open market transaction. The shares were sold at an average price of Rs 231.50 apiece.

OrbiMed divested a 2.27% stake in Marksans Pharma for Rs 257 crore through an open market transaction. The sale reduced OrbiMed's holding to 8.61%.

Indian pharma stocks plunged on Wednesday following reports that the US will soon announce tariffs on pharmaceutical imports. Blue Jet Healthcare, Marksans Pharma, Wockhardt, Glenmark...

Pharmaceutical stocks tumbled up to 10% after reports of Trump imposing tariffs on imports. Aurobindo, Laurus, Ipca, Lupin, Biocon, and Cipla were among the hardest hit.

Report: Shorter Gen Z job tenures in GCCs push replacement hiring to 40% in Q4. GCCs balance expansion with continuity.

IntelliSmart wins 5.57-lakh smart meter project in Madhya Pradesh. Expands footprint, contributing to India's energy transformation under RDSS.

Bank of Maharashtra shares surge 4% after reporting a 35% rise in Q4 net profit. Key highlights include increased income and improved asset quality.

Bank of Maharashtra reports 35% jump in Q4 profit to Rs 2,014 cr. Aims to raise Rs 7,500 cr for growth. Details on NPAs, CASA, and dividends.

RBI draft on upper layer NBFCs disproportionately affects CICs, raising compliance costs. Mandatory listing is onerous for some.

Report: Shorter Gen Z job tenures in GCCs push replacement hiring to 40% in Q4. GCCs balance expansion with continuity.

IntelliSmart wins 5.57-lakh smart meter project in Madhya Pradesh. Expands footprint, contributing to India's energy transformation under RDSS.

Bank of Maharashtra shares surge 4% after reporting a 35% rise in Q4 net profit. Key highlights include increased income and improved asset quality.

Bank of Maharashtra reports 35% jump in Q4 profit to Rs 2,014 cr. Aims to raise Rs 7,500 cr for growth. Details on NPAs, CASA, and dividends.

RBI draft on upper layer NBFCs disproportionately affects CICs, raising compliance costs. Mandatory listing is onerous for some.